Hot Deals:
a v thomas 13,300.00 (1.53 %) adtech 27.05 (0.19 %) agarwal bolts 1,201.00 (0.08 %) amol minechem 620.00 (1.64 %) anand i-power 20.00 anglo french 370.00 (-2.37 %) aricent 515.00 (0.98 %) arkfin investments 50.00 arohan 170.00 (-0.58 %) assam carbon 208.00 (-0.95 %) associated pigments 42.01 (0.02 %) atlas copco 10,000.00 (1.01 %) auckland international 130.00 (-3.70 %) axles 162.00 (1.25 %) balmer lawrie 197.00 (-1.50 %) bharat hotels 149.00 (-0.67 %) bima mandi 700.00 bira 91 750.00 (-2.85 %) boat 830.00 (3.75 %) c & s electric 471.00 (0.21 %) capgemini 12,100.00 (-0.82 %) care health 150.00 (2.04 %) carrier aircon 260.00 (1.96 %) cial 179.00 (0.56 %) csfbl 264.00 (-0.38 %) csk 168.00 (1.20 %) dalmia refract 82.00 (1.23 %) dsp merrill lynch 1,000.00 east india pharma 44.00 (2.33 %) eaton fluid 414.00 (2.22 %) electronica plastic 4,110.00 (0.24 %) elgi ultra 400.00 elofic 1,925.00 (0.84 %) esl steel 38.00 (2.70 %) fincare business 43.00 fincare sfbl 74.00 (1.37 %) fino paytech 155.00 (-1.90 %) flipkart 231,000.00 (0.00 %) frick india 2,800.00 (-3.45 %) gkn drive 1,161.00 (0.09 %) go digit gil 354.00 (1.14 %) godavari bio 71.00 (1.43 %) hdbfsl 625.00 (2.46 %) hdfc ergo 370.00 (1.70 %) hdfc securities 11,400.00 (2.70 %) hella india 375.00 (-0.53 %) hero fincorp 680.00 (-1.45 %) hicks 1,579.00 (-1.31 %) hira ferro 120.00 (-0.83 %) honeywell electrical 3,333.00 (-1.97 %) icex 0.10 (0.10 %) incred financial 100.00 india carbon 1,010.00 (1.00 %) india exposition 146.00 (0.69 %) indian potash 1,405.00 (0.36 %) indofil 703.00 (0.43 %) infinite computer 700.00 inkel 12.00 (-1.64 %) ixigo 72.00 (-2.70 %) jana sfbl 75.00 kel 460.00 (2.22 %) kial 107.00 (-2.73 %) kurlon limited 292.00 (0.69 %) lava 127.00 (0.79 %) manipal housing 72.50 (0.69 %) manjushree tech 990.00 (2.06 %) martin & harris 1,240.00 (-0.80 %) merino 2,775.00 (0.18 %) minosha 280.00 (-3.45 %) mitsubishi heavy 355.00 (1.43 %) mkcl 400.00 (-3.61 %) mobikwik 390.00 (-2.50 %) mohan meakin 1,210.00 (0.83 %) mohfl 8.10 (1.25 %) msei 1.00 (1.01 %) msil 57.00 (1.79 %) nayara energy 150.00 (-1.32 %) nayara energy ncd 250.00 ncdex 275.00 ncl buildtek 190.00 (-0.52 %) ncl holdings 53.00 (1.92 %) nse 3,100.00 (-1.59 %) orbis financial 81.00 (1.25 %) oswal minerals 65.00 (1.56 %) otis 3,600.00 (-2.70 %) oyo rooms 68.00 (-1.45 %) panasonic appliances 295.00 (0.68 %) panasonic avc 29.10 (0.34 %) paymate india 600.00 (-3.38 %) pharmeasy 29.00 (-3.01 %) philips domestic 605.00 (0.83 %) philips india 979.00 (-1.11 %) pnb metlife 70.00 proyuga adtech 25.00 purity flexpack 20.00 ramaraju surgical 390.00 (-2.50 %) rasoi 31,400.00 (-1.88 %) reliance gic 340.00 resins plastics 414.00 (1.97 %) ring plus 405.00 (2.27 %) rrl 2,525.00 (-2.88 %) sab miller 305.00 (0.66 %) scottish assam 443.00 (-1.56 %) shriram life 251.00 (0.40 %) sigachi lab 40.10 (0.25 %) signify 1,161.00 (0.96 %) simpson & company 3,500,000.00 smile micro 52.00 (-1.89 %) sportskeeda 3,303.00 sterlite power 485.00 (-3.00 %) studds 850.00 (-2.30 %) svsml 430.00 (-2.27 %) t stanes 601.00 (0.17 %) tata capital 56.00 (1.82 %) tata tech 740.00 (2.78 %) teesta agro 60.00 (-1.64 %) trl krosaki 1,200.00 (-1.96 %) utkarsh coreinvest 127.00 (-2.31 %) vikram solar 55.50 (-0.89 %)
×

arch pharma labs Limited

55.00
+ 1.85 %
Scrip Name
Arch Pharma
ISIN No.
INE182F01017
PAN No.
AACCM0306Q
Face Value
10
No. of Outstanding Shares
151,923,000
Market Capitalization
835.58 Crore
Book value
15.087
P/BV
3.646
EPS
123.052
PE ratio
0.447
Available on
nsdlcdsl
ROFR Required
No

About ARCH PHARMA LABS LIMITED Unlisted/Delisted Share

ARCH PHARMA LABS LIMITED is a pharmaceutical company aligned across two business verticals viz. Products and Services. The Products business of the company comprises the manufacture and sale of Active Pharmaceutical Ingredients (“API”) and Intermediates to innovator and generic pharmaceutical players in both domestic and international markets including the regulated markets. In services business of the company includes Contract Research and Manufacturing Services (“CRAMS”). Currently, the company owns and manages 9 multipurpose manufacturing facilities.

The Company has a diversified portfolio and offers more than 120 products ( over 65 APIs and over 55 Intermediates) across various therapeutic segments, such as lipid-lowering agents, oncology, anti-platelet agents, anti-asthmatic,anti-retroviral, anti-anginal, calcium channel blockers, anti-hypertensive,anti-histamine, anti-diabetic, anti-protozoal, anti-fungal, anti-emetic, proton pump inhibitors, expectorant, anti-depressant, decongestant, anti-convulsant, psychostimulant, hypnotic, anti-parkinsonian, anti-gout, analgesic, and others.

The Company provides contract manufacturing, custom synthesis, and contract research services comprising route selection, process development, optimization, analytical development, stability studies, safety studies, scale-up to technology transfer, clinical-trial manufacturing, and commercial manufacture.

Arch Pharmalabs Limited has technology tie-ups with Codexis (USA), Orochem Technologies (USA), and DSM (Netherlands). The use of these technologies helps the company to implement various green chemistry initiatives which are not only environmentally friendly but also reduce production costs.

INCORPORATION DETAILS

CIN

U24231MH1993PLC150891

Registration Date

02 April 1993

Category/Sub-category of the Company

Company Limited by Shares

Address of the Registered office and contact details

3rd Floor, Titanic Building, Chandivali Farm Road,

Nr. HDFC Bank, Andheri (East), Mumbai - 400072.

Tel. : +91-22-4287 1210

Name, Address and Contact Details of

Registrar and Transfer Agent, if any

Link Intime India Private Limited

C-101, 247 Park, L.B.S Marg,

Vikhroli (West), Mumbai - 400083,

Tel: 022-25946970

 

PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

Name and Description of main products/services

NIC Code of the product/service

% to total turnover of the Company

Pharmaceutical products

21002 & 21005

100%

 

BOARD OF DIRECTORS

Mr. Ajit Kamath (Chairman & Managing Director)

Mr. Rajendra Kaimal (Executive Director & CFO)

Mr. Ashish Ujagare (Executive Director)

Dr. Sunil Pitroda (Independent Director)

 

PARTICULARS OF SUBSIDIARY AND ASSOCIATE COMPANIES

Name of the Company

Subsidiary/Associate

% of shares held

Arch Life SciencesLimited

Subsidiary

58.46%

Arch FinechemicalsLimited

Subsidiary

88.95%

Arch Pharmalabs FZLLC

Subsidiary

100.00%

Kobo Biotech Limited

Associate

44.95%

 

SHAREHOLDING PATTERN

(As of 31-03-2020)

S. No.

Shareholders’ Name

Number of shares

% of total Shares of the company

1

Arch Impex Private Limited

5,54,05,664

36.47%

2

Arch PharmachemLimited

2,11,81,000

13.94%

3

ArchAgroIndustriesPrivate Limited

61,54,754

4.05%

4

AMR InvestmentsPrivate Limited

19,76,681

1.30%

5

Arch Herbals Private limited

62,42,076

4.11%

6

Public Shareholding

6,09,62,901

40.12%

 

Total

15,19,23,076

100.00%

 

INDUSTRY OUTLOOK

 

The Global pharmaceutical industry is valued at around US$ 1250 billion. The US market alone accounts for 48% of the market. India and China each stand at US$ 53 billion and US$ 190 billion respectively. India is the largest provider of generic drugs and is fulfilling around 20% of the global demand.

 

In the Active Pharmaceutical Ingredients (API) Industry, if we see the units approved by USFDA, US leads with 28% approval rating, Europe with 26%, and India & China with 18% and 13% respectively. It is the best time for India to focus on building and improving its API manufacturing and export capabilities. According to Statistics, the Indian API market is projected to grow at a CAGR of 8.57% from 2020 to 2026. The Government of India has announced Rs. 6,940 Crore Production Linked Incentive (PLI) scheme to boost drug manufacturing in India. The scheme is mainly aimed at reducing imports through the promotion of domestic manufacturing of Active Pharmaceutical Ingredients (APIs) and Drug Intermediates.

 

Pharmaceutical Companies are continuously increasing outsourcing research activities to academic and private contract research organizations (CROs) to become and stay competitive in the market. After the COVID 19 pandemic, the pharmaceutical industry has gotten a new direction and is currently experiencing dynamic changes. That is why to reduce their R&D expenses, the companies to a significant extent are now relying on outsourcing service providers. Based on this, the opportunities available to India are Custom Chemical Synthesis or CCS, clinical trials, and contract manufacturing or CRAMS. However, the most scalable opportunity for Indian companies lies in contract manufacturing or CRAMS. This is because CRAMS supplies are linked to the success of a product post commercialization and can provide relatively stable revenues.

 

PROFIT & LOSS STATEMENT OF ARCH PHARMA LABS LIMITED(In Rs. Crores)

 

Particulars

FY 2020

FY 2019

FY 2018

Revenue from Operations

632.29

476.58

247.19

EBITDA

38.43

14.05

-263.02

Finance Cost

204.67

162.84

82.52

Depreciation

30.30

32.54

39.10

Other Income

19.22

38.20

0.25

Profit Before Tax and Exceptional items

-177.32

-143.12

-384.39

Exceptional items

17.13

12.14

323.25

Total Tax

-0.69

0.34

0.00

Profit After Tax (PAT)

-159.50

-131.31

-61.14

EPS

-10.5

-8.64

-8.92

 

BALANCE SHEET OF ARCH PHARMA LABS LIMITED (In Rs. Crores)

 

PARTICULARS

2020

2019

ASSETS

   

NON-CURRENT ASSETS

   

Tangible assets

998.36

1052.33

Intangible assets

5.18

9.17

Goodwill ( On Consolidation)

9.71

9.71

Financial assets

207.11

207.33

TOTAL NON-CURRENT ASSETS

1,220.36

1,278.55

CURRENT ASSETS

   

Inventories

832.58

729.71

Trade receivables

439.39

589.61

Cash and Cash Equivalents

2.77

4.19

Short-term loans and advances

614.29

628.74

TOTAL CURRENT ASSETS

1,889.02

1,952.25

TOTAL ASSETS

3,109.38

3,230.80

EQUITY AND LIABILITIES

   

Share Capital

151.92

151.92

Share Application Money

17.51

17.51

Surplus

-1,776.35

-1,582.75

Minority Interest

3.39

3.39

TOTAL EQUITY

-1,603.52

-1,409.92

NON-CURRENT LIABILITIES

   

Long-term borrowings

3,070.84

3,451.14

TOTAL NON-CURRENT LIABILITIES

3,070.84

3,451.14

CURRENT LIABILITIES

   

Short-term borrowings

113.12

113.22

Trade payables

475.48

550.94

Other current liabilities

1,048.25

520.22

Short-term provisions

5.21

5.21

TOTAL CURRENT LIABILITIES

1,642.06

1,189.58

TOTAL LIABILITIES

4,712.90

4,640.72

TOTAL EQUITY AND LIABILITIES

3,109.38

3,230.80

 

DIVIDEND HISTORY

Particulars

2020

2019

2018

Dividend (final + interim) (In Rs.)

Nil

Nil

Nil

 

PERFORMANCE OF THE COMPANY

The revenue from operations of the company increased by 32.67% from Rs. 486.58 Crore in FY 2019 to Rs. 632.29 Crore in FY 2020. The increase in revenue can mainly be attributed to the increase in operational activities at the manufacturing sites and is expected to continue in the coming few years.

EBITDA of the company has increased by 173% from Rs. 14.05 Crore in FY 2019 to Rs. 38.43 Crore in FY 2020. EBITDA margins have improved from 2.95% in FY 2019 to 6.08% in FY 2020.

The finance cost of the company increased by 25.68% from Rs. 162.84 Crore in FY 2019 to Rs. 204.67 Crore in FY 2020.

The company has incurred a loss of Rs. 131.31 Crore in FY 2019, which increased to a loss of Rs. 159.50 Crore in FY 2020. These losses are mainly because of the increasing financial cost of the company.

The current Ratio of the company as of 31st March 2020 was 1.15.

The Company has not given any dividend for the past three years.

Wealth Wisdom - WWIPL
Support Megha Support Neha Support Pallavi